Work

Integrating cell-level kinetic modeling into the optimization of cancer therapeutics

Year: 2010
Type: dissertation
Abstract: Cancer therapy bene ts today from the availability of new promising classes of drugs such as\ntherapeutic proteins. Due to their ability to speci cally bind targets in the body they allow to\nmodulate speci c chemical reactions and ultimately to modify the functional response of the\ncell, such as cell growth or cell division. Targeting receptor systems by competitive inhibition\nis the objective of various protein drugs in development and on the market. Many targeted\nreceptor systems also constitute a degradation mechanism for the drug via endocytosis and a\nthorough understanding of the complex interplay between the drug's pharmacokinetics and\nits e ect, is largely missing.\nFor complex diseases such as cancer, systems biology models of therapeutically relevant\ncellular processes have proven valuable for identifying potent drug targets. So far, such\ninformation about the dynamics of the targeted system is neglected in later stages of the drug\ndevelopment process when pharmacokinetic modeling is used to guide dose nding and analyze\npreclinical or clinical in vivo data. This is especially critical for therapeutic proteins where,\ndue to the degradation mediated by the targeted receptor, drug e ect and pharmacokinetics\nare inherently interdependent.\nThis thesis combines the points of view of systems biology and pharmacokinetics. We\npresent a detailed mechanistic model of the targeted cellular system that explicitly takes into\naccount receptor binding and tra cking inside the cell and that is used to derive reduced\nmodels of drug degradation which retain a mechanistic interpretation. By integrating celllevel\nmodels with established pharmacokinetic models, we translate biophysical properties\nof protein drugs into a transient drug e ect in vivo. We illustrate the approach for antibodies\nagainst the epidermal growth factor receptor used in cancer therapy. The cell-level\npharmacokinetic/pharmacodynamic model identi es options and limits for future therapeutic\nantibodies and links their inhibitory e ect with genomic alteration of tumor cells.
Language: English
Subfield: Immunology
Open Access status: green
OpenAlex ID: W1505535880
Cites: 157
Cited by:
Related to: 9